Skip to main content

clostridium botulinum neurotoxin type A (Xeomin®)

 

Status: Recommended

Clostridium botulinum neurotoxin type A (Xeomin®) is recommended as an option for use within NHS Wales for the symptomatic treatment in children and adolescents aged 2 to 17 years and weighing ≥ 12 kg of chronic sialorrhoea due to neurological/neurodevelopmental disorders.

This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.

 Final Recommendation: clostridium botulinum (Xeomin) 3986 (PDF, 325Kb)

Medicine details

Medicine name clostridium botulinum neurotoxin type A (Xeomin®)
Formulation 50 units powder for solution for injection, 100 units powder for solution for injection, 200 units powder for solution for injection
Reference number 3986
Indication

Symptomatic treatment in children and adolescents aged 2 to 17 years and weighing ≥ 12 kg of chronic sialorrhoea due to neurological/neurodevelopmental disorders

Company Merz Pharma UK Ltd
BNF chapter Central nervous system
Submission type Licence extension for paediatric use
Status Recommended
Advice number 2021
AWMSG meeting date 08/12/2021
Date of issue 10/12/2021
Commercial arrangement PAS
Further information

See also TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (in adults)

Follow AWTTC: